Gasto económico del tratamiento del dolor irruptivo

This article presents two pharmacoeconomic studies comparing the compressedfentanyl lozengewith an integral oromucosalapplicator (Actiq®); fentanyl sublingual tablets(Abstral®); effervescent fentanyl buccal tablets(Effentora®) and nasal fentanyl with two technologies: a formulation that contains pectin in a gel-based nasal spray (PecFent®) and another formulation in an aqueous solution without pectin (Instanyl®). The first of these studies aimed to analyze the potential savings due to the progressive introduction of fentanyl pectin nasal spray for the treatment of adult patients with breakthrough cancer pain. The second study aimed to determine the effectiveness and efficiency of fentanyl pectin nasal spray compared with the other tansmucosal treatments currently on the market. The first study showed a reduction in healthcare costs with the progressive introduction of fentanyl pectin nasal spray for the treatment of breakthrough pain in the publicly-funded health system in Spain. The second study showed that the most efficient option (greatest effectiveness and lowest cost) in all the cases analyzed was the fentanyl-pectin nasal spray.